<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0256-9574</journal-id>
<journal-title><![CDATA[SAMJ: South African Medical Journal]]></journal-title>
<abbrev-journal-title><![CDATA[SAMJ, S. Afr. med. j.]]></abbrev-journal-title>
<issn>0256-9574</issn>
<publisher>
<publisher-name><![CDATA[Health and Medical Publishing Group]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0256-95742012000900022</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[South African measles outbreak 2009 - 2010 as experienced by a paediatric hospital]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[le Roux]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[le Roux]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<xref ref-type="aff" rid="A02"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Nuttall]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Eley]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
</contrib-group>
<aff id="A01">
<institution><![CDATA[,University of Cape Town Red Cross War Memorial Children's Hospital Department of Paediatrics and Child Health]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<aff id="A02">
<institution><![CDATA[,University of Cape Town Red Cross War Memorial Children's Department of Paediatrics and Child Health]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>09</month>
<year>2012</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>09</month>
<year>2012</year>
</pub-date>
<volume>102</volume>
<numero>9</numero>
<fpage>760</fpage>
<lpage>764</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.za/scielo.php?script=sci_arttext&amp;pid=S0256-95742012000900022&amp;lng=en&amp;nrm=iso&amp;tlng=en"></self-uri><self-uri xlink:href="http://www.scielo.org.za/scielo.php?script=sci_abstract&amp;pid=S0256-95742012000900022&amp;lng=en&amp;nrm=iso&amp;tlng=en"></self-uri><self-uri xlink:href="http://www.scielo.org.za/scielo.php?script=sci_pdf&amp;pid=S0256-95742012000900022&amp;lng=en&amp;nrm=iso&amp;tlng=en"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[INTRODUCTION: Between 2009 and 2010, South Africa experienced a major measles outbreak, with more than 18 000 confirmed cases reported to the National Institute of Communicable Diseases. METHODS: We studied measles admissions during the outbreak to Red Cross War Memorial Children's Hospital, Cape Town, between 1 November 2009 and 31 July 2010. Factors associated with mortality were retrospectively identified from notification records and hospital admissions data. Multivariate logistic regression was used to investigate potential risk factors for death. RESULTS: In total, 1 861 children were diagnosed with measles; 552 (30%) were admitted to hospital. The most common reason for admission was pneumonia (379 (68%)) and/or diarrhoea (262 (48%)). The median age at admission was 7.36 months (interquartile range (IQR) 5.0 - 10.7). The median duration of admission was 4 days (IQR 2 - 6); total hospital admission time was 3 746 days (10.3 child-years). HIV status was known in 404 (73%) children: 39/400 (14%) were HIV-infected. Eighteen children died (3% of all admissions); 15 (83%) of them were less than 1 year old. In the regression model, HIV-infection (adjusted odds ratio (aOR) 7.55, 95% confidence interval (CI) 2.27 - 25.12) and female sex (aOR 3.86, 95% CI 1.26 - 11.84) were associated with higher odds of death. CONCLUSIONS: There was a large paediatric admission burden during the 2009 - 2010 measles outbreak in Cape Town; young children were predominantly affected. HIV-infected children had a significantly higher case fatality.]]></p></abstract>
</article-meta>
</front><body><![CDATA[ <p align="right"><font face="Verdana, Arial, Helvetica, sans-serif" size="2"><b>RESEARCH</b></font></p>     <p>&nbsp;</p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="4"><b>South African    measles outbreak 2009 - 2010 as experienced by a paediatric hospital</b></font></p>     <p>&nbsp;</p>     <p>&nbsp;</p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"><b>David M le Roux<sup>I</sup>;    Stanzi M le Roux<sup>IV</sup>; James J Nuttall<sup>II</sup>; Brian S Eley<sup>III</sup></b></font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"><sup>I</sup>MB    ChB, DTM&amp;H, FCPaed (SA), MMed (Paed), MPH. Infectious Diseases Unit, Department    of Paediatrics and Child Health, Red Cross War Memorial Children's Hospital    and University of Cape Town    <br>   <sup>II</sup>MB ChB, FCPaed (SA), DTM&amp;H. Infectious Diseases Unit, Department    of Paediatrics and Child Health, Red Cross War Memorial Children's Hospital    and University of Cape Town    <br>   <sup>III</sup>MB ChB, BSc, FCPaed (SA). Infectious Diseases Unit, Department    of Paediatrics and Child Health, Red Cross War Memorial Children's Hospital    and University of Cape Town    <br>   <sup>IV</sup>MB ChB, DCH. Department of Paediatrics and Child Health, Red Cross    War Memorial Children's Hospital and University of Cape Town </font></p>     ]]></body>
<body><![CDATA[<p>&nbsp;</p>     <p>&nbsp;</p> <hr size="1" noshade>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"><b>ABSTRACT</b></font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"><B>INTRODUCTION:</b>    Between 2009 and 2010, South Africa experienced a major measles outbreak, with    more than 18 000 confirmed cases reported to the National Institute of Communicable    Diseases.    <br>   <b>METHODS:</b> We studied measles admissions during the outbreak to Red Cross    War Memorial Children's Hospital, Cape Town, between 1 November 2009 and 31    July 2010. Factors associated with mortality were retrospectively identified    from notification records and hospital admissions data. Multivariate logistic    regression was used to investigate potential risk factors for death.    <br>   <b>RESULTS:</b> In total, 1 861 children were diagnosed with measles; 552 (30%)    were admitted to hospital. The most common reason for admission was pneumonia    (379 (68%)) and/or diarrhoea (262 (48%)). The median age at admission was 7.36    months (interquartile range (IQR) 5.0 - 10.7). The median duration of admission    was 4 days (IQR 2 - 6); total hospital admission time was 3 746 days (10.3 child-years).    HIV status was known in 404 (73%) children: 39/400 (14%) were HIV-infected.    Eighteen children died (3% of all admissions); 15 (83%) of them were less than    1 year old. In the regression model, HIV-infection (adjusted odds ratio (aOR)    7.55, 95% confidence interval (CI) 2.27 - 25.12) and female sex (aOR 3.86, 95%    CI 1.26 - 11.84) were associated with higher odds of death.    <br>   <b>CONCLUSIONS:</b> There was a large paediatric admission burden during the    2009 - 2010 measles outbreak in Cape Town; young children were predominantly    affected. HIV-infected children had a significantly higher case fatality.</font></p> <hr size="1" noshade>     <p>&nbsp;</p>     <p>&nbsp;</p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">Measles vaccination    has been very effective in reducing the global measles disease burden. However,    outbreaks can occur when inadequate vaccination coverage allows accumulation    of a sufficient number of susceptible individuals in a population. The estimated    level of population immunity needed to prevent measles outbreaks is about 95%.<sup>1</sup>    South Africa introduced routine measles vaccination in 1975, and measles became    a notifiable condition in 1979. In 1995, the current 2-dose strategy (routine    vaccination at 9 and 18 months) was adopted. Case-based surveillance was introduced    in 1998, with all suspected cases having blood or urine tested at the National    Institute of Communicable Diseases (NICD).<sup>2</sup></font></p>     ]]></body>
<body><![CDATA[<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">Accurate coverage    of measles vaccination has been difficult to determine. In 2009, the South African    Department of Health (DoH) estimated national coverage with routine measles    vaccine to be 99%, but the World Health Organization (WHO) and United Nations    Children's Fund (UNICEF) coverage estimates were only 65%.<sup>3</sup> In 2004,    a survey in Western Cape Province found 79% of children to be 'fully vaccinated'.<sup>4</sup>    In 2005, another study estimated that 93% of children had received the first    dose of measles vaccine, but only 60% a second dose.<sup>5</sup> The authors    concluded that routine coverage in the Western Cape was too low to prevent a    measles outbreak.</font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">The last major    outbreak in South Africa occurred in 1992. In July 2009, a cluster of measles    cases was detected in Tshwane; in August, the outbreak spread to Johannesburg,    and then rapidly throughout the rest of the country. The first case in the Western    Cape was confirmed in September 2009; there were 14 cases in October, and by    November the outbreak was well established throughout the Cape Town metropole.<sup>6</sup>    We report the epidemiology of measles cases presenting to a single paediatric    hospital in Cape Town.</font></p>     <p>&nbsp;</p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Methods</b></font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">Red Cross War Memorial    Children's Hospital (RXH) is a 290-bed, level 3 academic hospital in Cape Town.    During the outbreak, children with measles who needed admission were stabilised    and admitted to the 'short stay ward', from which they were either discharged    home, transferred to another hospital (mild disease), or admitted to the medical    wards or Intensive Care Unit (ICU) at RXH (severe disease or other significant    co-morbid disease).</font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">All children diagnosed    with measles at RXH between 1 November 2009 and 31 July 2010 were retrospectively    identified from paper notification records, electronic hospital admission records,    and the ICU database. Folders were reviewed and patients meeting the WHO clinical    case definition were included.<sup>7</sup> Suspected measles cases that tested    negative for measles IgM antibodies were excluded. Data were captured onto a    paper form and entered into an electronic database. Final discharge dates and    re-admission dates were extracted from the city-wide hospital admission computer    system; this includeD all the time spent in any hospital in the city.</font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">All children were    managed according to written hospital protocols. In-patient management of pneumonia    included intravenous ampicillin, gentamicin and cloxacillin. Vitamin A was dosed    according to WHO guidelines.<sup>7</sup> During the outbreak, all children attending    RXH who did not have clinical measles were given measles prophylaxis. Children    older than 6 months were given a single dose of intramuscular measles vaccine    (Rouvax, Sanofi Pasteur, France); children under 6 months and children with    severe immunosuppression were given an intramuscular dose of human immunoglobulin    (Intragam, National Bioproducts Institute, South Africa), according to the manufacturer's    instructions.</font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">HIV testing was    performed when deemed clinically appropriate by the treating clinicians. Children    &gt;18 months old were considered HIV-infected if HIV antibodies were detected    by enzyme-linked immunosorbent assay (ELISA) testing. Results were confirmed    on a second specimen with a manual ELISA (Enzygnost Anti-HIV 1/2 Plus, Siemens    Healthcare Diagnostic Products GmbH, Marburg, Germany). Children &lt;18 months    old were considered HIV-infected with positive HIV DNA PCR (Cobas Ampliprep    system, Roche Molecular Systems, Branchburg, New Jersey, USA). Positive HIV    DNA PCR results were confirmed with HIV viral load testing.</font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">For summary statistics,    categorical data are expressed as number (percentage); continuous data are expressed    as median (inter-quartile range (IQR)). Median values were compared with the    Wilcoxon rank-sum test. Risk ratios were calculated to compare the proportion    of children who died or were re-admitted by gender and HIV status.</font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">Factors associated    with death were explored with multivariable logistic regression. We evaluated    the influence of age, sex, HIV status, immunisation status, evidence of vitamin    A administration, the presence of a 'Road to Health Card' and the weight-for-age    Z-score (calculated from growth charts from the Centers for Disease Control    and Prevention (CDC)). Weight-for-age Z-score of less than -2 was considered    'moderate underweight for age'; and less than -3 was considered 'severe underweight    for age'. Variables associated with the outcome at the </font><font  size="2">&#945;</font><font face="Verdana, Arial, Helvetica, sans-serif" size="2">=0.1    level were included for multivariable analysis. Automated backwards and forwards    step-wise model building procedures were used; potential models were compared    with Akaike's Information Criteria (AIC). Collinearity was assessed with variance    inflation factors. The final model chosen was most parsimonious and presented    the best AIC value. A sensitivity analysis was done to examine the influence    of the children with unknown HIV status. Analyses were done in Stata version    10 (Statacorp, College Station, Texas, USA). All p-values are two-tailed (</font><font  size="2">&#945;</font><font face="Verdana, Arial, Helvetica, sans-serif" size="2">=0.05).</font></p>     ]]></body>
<body><![CDATA[<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">Ethics approval    was obtained from the Department of Paediatrics and Child Health Departmental    Research Committee and the University of Cape Town Human Research Ethics Committee,    HREC-REF number 511/2010.</font></p>     <p>&nbsp;</p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Results</b></font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">From 1 November    2009 to 31 July 2010, 1 861 children with measles presented to RXH, who have    been categorised as follows.</font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Outpatients</b></font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">In total, 1 309    (70%) children were treated as outpatients; most presented in March and April    2010 (<a href="#f1">Fig. 1</a>). The median age was 8.9 months (IQR 6.1 - 30.4)    (<a href="/img/revistas/samj/v102n9/22t01.jpg">Table 1</a>). Documentation of    measles vaccination status in the hospital notes was poor: of the 565 children    eligible for routine measles vaccination, only 270 (48%) had vaccination status    recorded, and only 68% had vitamin A administration documented in the hospital    notes (<a href="/img/revistas/samj/v102n9/22t01.jpg">Table 1</a>).</font></p>     <p><a name="f1"></a></p>     <p>&nbsp;</p>     <p align="center"><img src="/img/revistas/samj/v102n9/22f01.jpg"></p>     <p>&nbsp;</p>     ]]></body>
<body><![CDATA[<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Admissions</b></font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">There were 552    hospital admissions; inpatients were significantly younger than children treated    only as outpatients (median age 7.4 months v. 8.9 months, Wilcoxon p&lt;0.0001)    (<a href="/img/revistas/samj/v102n9/22t01.jpg">Table 1</a>). Most children (357/552    (65%)) were younger than 9 months (the age of routine measles vaccination) (<a href="#f2">Fig.    2</a>). At least 379 (63%) children presented with pneumonia, 262 (47%) with    severe diarrhoea and 163 (30%) with both. Other reasons for admission included    croup (37 (7%)), and suspected meningitis (2 (0.4%)). Vaccination status was    recorded in the hospital notes in 92/195 (47%) children older than 9 months;    suspected measles; 96 (17%) had detectable measles IgM antibodies; 4 specimens    were invalid or insufficient. Only 2 children with clinically-suspected measles    were confirmed measles IgM negative; both children had detectable rubella IgM    antibodies, and were excluded from this analysis.</font></p>     <p><a name="f2"></a></p>     <p>&nbsp;</p>     <p align="center"><img src="/img/revistas/samj/v102n9/22f02.jpg"></p>     <p>&nbsp;</p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">Of the admitted    children, 404 (73%) had known HIV status: 39/404 (10%) were HIV-infected, of    whom 20/39 (51%) had been on antiretroviral therapy (ART) for more than 3 months.    All HIV-infected children with severe measles subsequently commenced ART. Only    3/23 (14%) HIV-infected, vaccine-eligible children had documentation of any    measles vaccination.</font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"> <b>Deaths and    complications</b></font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">Of all admissions,    18 (3%) children died, of whom 13 (72%) were less than 1 year old; 11 (61%)    deaths were due to respiratory failure; other causes included septic shock with    multi-organ failure (4 children (22%)) and cerebral ischaemia after cardio-respiratory    arrest (2 children (11%)). One child died from massive bowel ischaemia and necrosis.</font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">Of HIV-infected    children 7/39 (18%) died v. 11/365 (3%) known HIV-uninfected children. Case    fatality was 5% among girls v. 1.7% of boys (<a href="#t2">Table 2</a>). In    multivariable logistic regression adjusted for age and weight-for-age, HIV infection    and gender remained strong predictors of mortality (<a href="#t3">Table 3</a>).    Of HIV-infected children who died, 2/7 (29%) had received ART for at least 3    months.</font></p>     ]]></body>
<body><![CDATA[<p><a name="t2"></a></p>     <p>&nbsp;</p>     <p align="center"><img src="/img/revistas/samj/v102n9/22t02.jpg"></p>     <p>&nbsp;</p>     <p><a name="t3"></a></p>     <p>&nbsp;</p>     <p align="center"><img src="/img/revistas/samj/v102n9/22t03.jpg"></p>     <p>&nbsp;</p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">During the study    period, 4 children with complications of measles required tracheostomies (Sr    Jane Booth, personal communication). One child was referred with severe croup;    3 children developed upper airway damage following prolonged intubation and    ventilation for severe pneumonia. All 4 entered the RXH home tracheostomy programme    and were discharged home within 2 months of their admission but had recurrent    re-admissions with respiratory infections. By March 2012, 3 children had been    successfully decannulated, and one remains with a tracheostomy.</font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Length of stay    and re-admissions</b></font></p>     ]]></body>
<body><![CDATA[<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">The median duration    of admission was 4 days (IQR 2 - 6 days). HIV-infected children were admitted    for longer (median 6 days, IQR 4 - 14 days) than HIV-uninfected children (median    3 days, IQR 2 - 5 days; Wilcoxon <i>p</i>=0.0007).</font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">Among survivors,    53/287 (18%) of boys were re-admitted v. 19/247 (8%) of girls (risk ratio (RR)    for re-admission 2.40 (95% CI 1.46 - 3.94, p=0.0003)). Moderate or severe underweight    for age (weight for age Z-score less than -2) was also strongly associated with    readmission: of 531 surviving children with known weight-forage, 26/113 (23%)    who were moderately or severely underweight for age were re-admitted v. 46/418    (11%) of children who were not underweight for age, RR 2.09 (95% CI 1.36 - 3.23,    p=0.0009). Of HIV-infected children, 28% (9/32) were re-admitted v. 12% (44/354)    HIV-uninfected children (RR 2.26, 95% CI 1.22 - 4.20, p=0.01).</font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">Total primary hospital    admission time was 3 746 days (10.3 child-years). Of the 534 surviving children,    72 (13%) were re-admitted within 90 days; 24 of these children (24/534 (4% of    all the survivors)) were re-admitted a third time within 90 days of their first    admission. The total time spent in hospital, including the primary admission    and subsequent re-admissions within 3 months of discharge, was 4 477 days (12.3    child-years). This constitutes 6.6% of total in-patient days at RXH during the    study period.</font></p>     <p>&nbsp;</p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Discussion</b></font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">Between April 2009    and November 2010, South Africa experienced a national measles outbreak, with    18 311 serologically confirmed measles cases. Almost a quarter of these cases    were infants younger than 9 months.<sup>8</sup> The magnitude was probably even    greater, as many cases were diagnosed clinically: in our institution, only 96/552    (17%) measles admissions were laboratory confirmed.</font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">At RXH, the main    burden of disease, in terms of hospitalisations and mortality, was in infants    &lt;1 year old. There was an especially high burden in infants younger than    6 months. There are several reasons why the very young were so severely affected.    Children become susceptible to measles infection once maternally-derived transplacental    antibody levels are below a protective threshold. Vaccinated women transfer    fewer antibodies than mothers whose immunity followed wild-type measles infection.    In Belgium, babies of vaccinated women received a third of measles-specific    antibodies v. babies born to women with immunity owing to natural measles infection.<sup>9</sup>    The antibodies are also lost more quickly: the median time to loss of immunity    was 0.97 months for babies born to vaccinated women v. 3.78 months for babies    born to women with previous measles infection.<sup>9</sup></font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">In Cape Town, there    has been little circulating measles virus since the 1992 outbreak; most women    of childbearing age have not had natural measles infection. Since its inception    in 1975, the coverage of the measles immunisation programme has been too low;    many women have never been vaccinated. Their babies received no measles-specific    antibodies, rendering them susceptible to measles infection from a very young    age.</font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">Case fatality of    measles can range from 0.1% in developed countries to 30% in outbreaks among    refugee populations. The incidence is influenced by age, intensity of exposure    to measles virus, nutritional status, vaccination status, immune deficiency,    vitamin A administration, and access to appropriate case management.<sup>10</sup>    During the outbreak under review, case fatality among inpatients at RXH was    3% (18 deaths out of 552 admissions). Low weight-for-age Z-score was strongly    associated with increased mortality, with 35% increased odds of death for every    standard deviation below the expected weight for age. Furthermore, among survivors,    low weight for age Z-score doubled the risk of re-admission. The finding of    similar measles incidence among boys and girls, but with increased mortality    among girls, has previously been described,<sup>11</sup> but the biological    mechanism is not well understood.</font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">We observed increased    case fatality among inpatients with HIV-infection. They had an 18% case fatality    ratio, and 7 times higher odds of death than HIV-uninfected children, despite    half of them being established on ART. This figure is higher than previously    reported in areas with high HIV prevalence. In the 2003 - 2005 measles outbreak    in Johannesburg, 14% of known HIV-infected children died; they had a 3.3 times    higher risk of death than HIV-uninfected children.<sup>12</sup> In a 6-year    study in Zambia, case fatality among HIV-infected children was 12%, with 2.5    times higher odds of death than HIV-uninfected children.<sup>13</sup> Our higher    case fatality may reflect a selection bias for disease severity, as children    admitted to RXH had more severe disease than children treated as outpatients    or in other facilities in the city.</font></p>     ]]></body>
<body><![CDATA[<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">For several reasons,    HIV-infected children have a more severe clinical course than HIV-uninfected    children. HIV-infected children have deficient cellular and humoral immunity    and impaired innate immune responses.<sup>14</sup> Despite commencing ART, HIV-infected    children had twice the risk of re-admission v. HIV-uninfected children, which    may reflect the combined immune-suppressive effect of acute measles infection    in an already-compromised individual. HIV-infected children have suboptimal    responses to measles vaccination. Vaccination, even if not fully protective    against measles infection, can attenuate severity of disease.<sup>10</sup> In    HIV-uninfected children, response to measles vaccination is age-dependent, with    better antibody responses in older children. At 9 months, about 90% will develop    protective antibody levels (interquartile range 82 - 95%); at 12 months, 99%    will develop protective levels after a single dose of measles vaccine, (interquartile    range 93 - 100%).<sup>7</sup> However, the response in HIV-infected children    to vaccination does not improve with age. A meta-analysis of 26 studies of vaccine    responses in HIV-infected children at different ages showed highly variable    responses, but no trend towards improved seroconversion among older children.    The efficacy of a single dose of measles vaccine, whether given at 6, 9 or 12    months, was about 59% (95% CI 46 - 71%).<sup>15</sup> These studies only reported    attainment of protective antibody levels, and did not take into account T-cell    mediated immunity, effectiveness of protection from clinical disease, or the    effect of commencing ART. However, in a retrospective analysis of the 2003 -    2005 measles outbreak in Johannesburg, effectiveness of measles vaccine in preventing    clinical disease among HIV-infected children was calculated at 63%.<sup>12</sup>    Infants born to HIV-infected mothers who are themselves uninfected (HIV-exposed    but uninfected) also have increased susceptibility to measles infection. HIV-exposed    infants have lower levels of maternal antibody, and protective antibody is lost    earlier than in HIV unexposed infants.<sup>16</sup></font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">Among the children    admitted to hospital, there were 69 possible 'vaccine failures' - children with    a record of at least 1 dose of measles vaccine, who developed severe clinical    disease requiring admission. There are several possible explanations for these    vaccine failures. When vaccinations were documented, the admitting clinician    noted whether measles vaccine had been given, but not the date of administration.    It was not possible to determine retrospectively the age at vaccination or time    from vaccination till clinical disease. All children &gt;6 months old received    measles vaccine if they attended hospital, and there were 2 nationwide mass    vaccination campaigns (12 - 23 April and 24 - 28 May 2010). However, vaccination    of young children is less effective than of children &gt;1 year old.<sup>7</sup>    Some children might already have been infected with measles, but were vaccinated    while in the incubation period. All children &lt;6 months old seen at the hospital    who did not have measles were given measles immune globulin. If these children    were subsequently vaccinated, the immune globulin could impair vaccine effectiveness    for up to 9 months.<sup>17</sup> If they developed clinical measles despite    having had a vaccine dose recorded in their Road to Health Card, they would    be considered vaccine failures.</font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">This study has    several limitations. The data were captured retrospectively from clinical case    notes, much data had not been recorded, vaccine status was very poorly recorded,    and we were not able to explore many of the possible vaccine failures. Weight-for-height    is a better marker of malnutrition than weight-for-age, but few children had    their height measured. Some children with low weight-for-age Z-scores might    have been born pre-term, which might be a marker of low birthweight or pre-term    delivery, not adequacy of post-natal nutrition. Most of the clinically diagnosed    cases were not laboratory-confirmed. Dermatologists reviewing children admitted    with severe measles at another hospital in Cape Town during the epidemic found    a high correlation between clinically-suspected measles and laboratory-confirmed    measles. However, this might not apply to clinical diagnosis of mild disease    in outpatients.<sup>18</sup></font></p>     <p>&nbsp;</p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Conclusion</b></font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">The 2009 - 2010    measles outbreak was associated with a large case-load, and high morbidity and    mortality at RXH; &gt;65% of the admissions were for children aged &lt;9 months.    Measles is a preventable disease, given sufficient political will for the interruption    of measles transmission. Vaccine coverage must urgently be improved and supplementary    immunisation activities to under-serviced communities be targeted. HIV-infected    children had significantly higher case fatality and risk of re-admission. Prevention    of vertical transmission of HIV is a national priority, coverage of these programmes    must be extended, and early infant HIV diagnosis and treatment should be improved.</font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Acknowledgements.</b>    We thank data capturers Ida Oliphant, Santie Horn, Spasina King, Margaretha    Prins and Busi Skosana; and Jane Booth for information regarding the tracheostomy    and home ventilation programme.</font></p>     <p>&nbsp;</p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="3"><b>References</b></font></p>     <!-- ref --><p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">1.&nbsp;Moss WJ,    Griffin DE. Measles. Lancet 2012;379:153-164.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=552227&pid=S0256-9574201200090002200001&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">2.&nbsp;Uzicanin    A, Eggers R, Webb E, et al. Impact of the 1996-1997 supplementary measles vaccination    campaigns in South Africa. Int J Epidemiol 2002;31:968-976.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=552228&pid=S0256-9574201200090002200002&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">3.&nbsp;World Health    Organization: Vaccine Preventable Diseases Monitoring System 2011. <a href="http://apps.who.int/immunization_monitoring/en/globalsummary/countryprofileresult.cfm" target="_blank">http://apps.who.int/immunization_monitoring/en/globalsummary/countryprofileresult.cfm</a>    2010 (accessed 15 July 2011).</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=552229&pid=S0256-9574201200090002200003&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">4.&nbsp;Moodley    S. Immunisation coverage: Western Cape: Review of the data January 2001 - 2004.    Cape Town: Provincial Government of the Western Cape, 2004.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=552230&pid=S0256-9574201200090002200004&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">5.&nbsp;Corrigall    J, Coetzee D, Cameron N. Is the Western Cape at risk of an outbreak of preventable    childhood diseases? Lessons from an evaluation of routine immunisation coverage.    S Afr Med J 2008;98:41-45.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=552231&pid=S0256-9574201200090002200005&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">6.&nbsp;NICD NHLS.    Communicable Diseases Surveillance Bulletin 2009;7:15 July 2011.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=552232&pid=S0256-9574201200090002200006&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">7.&nbsp;World Health    Organization. Measles vaccines: WHO position paper. Wkly Epidemiol Rec 2009;84:349-    360.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=552233&pid=S0256-9574201200090002200007&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">8.&nbsp;NICD NHLS.    Communicable Diseases Communique. December 2010;9.</font></p>     <!-- ref --><p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">9.&nbsp;Leuridan    E, Hens N, Hutse V, Ieven M, Aerts M, Van Damme P. Early waning of maternal    measles antibodies in era of measles elimination: longitudinal study. BMJ 2010;340:c1626.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=552235&pid=S0256-9574201200090002200008&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">10.&nbsp;Cairns    KL, Nandy R, Grais RF. Challenges in measuring measles case fatality ratios    in settings without vital registration. Emerg Themes Epidemiol 2010;7:4.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=552236&pid=S0256-9574201200090002200009&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">11.&nbsp;Garenne    M. Sex differences in measles mortality: a world review. Int J Epidemiol 1994;23:632-642.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=552237&pid=S0256-9574201200090002200010&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">12.&nbsp;McMorrow    ML, Gebremedhin G, van den Heever J, et al. Measles outbreak in South Africa,    2003-2005. S Afr Med J 2009;99:314-319.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=552238&pid=S0256-9574201200090002200011&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">13.&nbsp;Moss WJ,    Fisher C, Scott S, et al. HIV type 1 infection is a risk factor for mortality    in hospitalized Zambian children with measles. Clin Infect Dis 2008;46:523-527.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=552239&pid=S0256-9574201200090002200012&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">14.&nbsp;Moss WJ,    Cutts F, Griffin DE. Implications of the human immunodeficiency virus epidemic    for control and eradication of measles. Clin Infect Dis 1999;29:106-112.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=552240&pid=S0256-9574201200090002200013&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">15.&nbsp;Scott    P, Moss WJ, Gilani Z, Low N. Measles vaccination in HIV-infected children: systematic    review and meta-analysis of safety and immunogenicity. J Infect Dis 2011;204    Suppl 1:S164-78.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=552241&pid=S0256-9574201200090002200014&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">16.&nbsp;Scott    S, Moss WJ, Cousens S, et al. The influence of HIV-1 exposure and infection    on levels of passively acquired antibodies to measles virus in Zambian infants.    Clin Infect Dis 2007;45:1417-1424.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=552242&pid=S0256-9574201200090002200015&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">17.&nbsp;American    Academy of Pediatrics. Measles. In: Pickering LK, Baker CJ, Kimberlin DW, Long    SS, eds. Red Book: 2009 Report of the Committee on Infectious Diseases. 28th    ed. Elk Grove Village, IL: American Academy of Pediatrics, 2009:448.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=552243&pid=S0256-9574201200090002200016&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">18.&nbsp;Tod G,    Carrara H, Levin M, Todd G. Dermatological manifestations of measles infection    in hospitalised paediatric patients observed in the 2009-2011 Western Cape epidemic.    S Afr Med J 2012;102:356.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=552244&pid=S0256-9574201200090002200017&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><p>&nbsp;</p>     <p>&nbsp;</p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">Accepted 18 June    2012.</font></p>     ]]></body>
<body><![CDATA[<p>&nbsp;</p>     <p>&nbsp;</p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Corresponding    author:</b> D le Roux (<a href="mailto:DrDaveleRoux@gmail.com">DrDaveleRoux@gmail.com</a>)</font></p>      ]]></body>
<REFERENCES></REFERENCES<back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Moss]]></surname>
<given-names><![CDATA[WJ]]></given-names>
</name>
<name>
<surname><![CDATA[Griffin]]></surname>
<given-names><![CDATA[DE]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Measles]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2012</year>
<volume>379</volume>
<page-range>153-164</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Uzicanin]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Eggers]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Webb]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Impact of the 1996-1997 supplementary measles vaccination campaigns in South Africa]]></article-title>
<source><![CDATA[Int J Epidemiol]]></source>
<year>2002</year>
<volume>31</volume>
<page-range>968-976</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="">
<collab>World Health Organization</collab>
<source><![CDATA[Vaccine Preventable Diseases Monitoring System]]></source>
<year>2011</year>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Moodley]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<source><![CDATA[Immunisation coverage: Western Cape: Review of the data January 2001 - 2004]]></source>
<year>2004</year>
<publisher-loc><![CDATA[Cape Town ]]></publisher-loc>
<publisher-name><![CDATA[Provincial Government of the Western Cape]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Corrigall]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Coetzee]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Cameron]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Is the Western Cape at risk of an outbreak of preventable childhood diseases?: Lessons from an evaluation of routine immunisation coverage]]></article-title>
<source><![CDATA[S Afr Med J]]></source>
<year>2008</year>
<volume>98</volume>
<page-range>41-45</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[NICD]]></surname>
<given-names><![CDATA[NHLS]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Communicable Diseases Surveillance]]></article-title>
<source><![CDATA[Bulletin]]></source>
<year>2009</year>
<volume>7</volume>
<page-range>15 July 2011</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<collab>World Health Organization</collab>
<article-title xml:lang="en"><![CDATA[Measles vaccines: WHO position paper]]></article-title>
<source><![CDATA[Wkly Epidemiol Rec]]></source>
<year>2009</year>
<volume>84</volume>
<page-range>349- 360</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Leuridan]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Hens]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Hutse]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Ieven]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Aerts]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Van Damme]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Early waning of maternal measles antibodies in era of measles elimination: longitudinal study]]></article-title>
<source><![CDATA[BMJ]]></source>
<year>2010</year>
<volume>340</volume>
<page-range>c1626</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cairns]]></surname>
<given-names><![CDATA[KL]]></given-names>
</name>
<name>
<surname><![CDATA[Nandy]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Grais]]></surname>
<given-names><![CDATA[RF]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Challenges in measuring measles case fatality ratios in settings without vital registration]]></article-title>
<source><![CDATA[Emerg Themes Epidemiol]]></source>
<year>2010</year>
<volume>7</volume>
<page-range>4</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Garenne]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Sex differences in measles mortality: a world review]]></article-title>
<source><![CDATA[Int J Epidemiol]]></source>
<year>1994</year>
<volume>23</volume>
<page-range>632-642</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McMorrow]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Gebremedhin]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[van den Heever]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Measles outbreak in South Africa, 2003-2005]]></article-title>
<source><![CDATA[S Afr Med J]]></source>
<year>2009</year>
<volume>99</volume>
<page-range>314-319</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Moss]]></surname>
<given-names><![CDATA[WJ]]></given-names>
</name>
<name>
<surname><![CDATA[Fisher]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Scott]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[HIV type 1 infection is a risk factor for mortality in hospitalized Zambian children with measles]]></article-title>
<source><![CDATA[Clin Infect Dis]]></source>
<year>2008</year>
<volume>46</volume>
<page-range>523-527</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Moss]]></surname>
<given-names><![CDATA[WJ]]></given-names>
</name>
<name>
<surname><![CDATA[Cutts]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Griffin]]></surname>
<given-names><![CDATA[DE]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Implications of the human immunodeficiency virus epidemic for control and eradication of measles]]></article-title>
<source><![CDATA[Clin Infect Dis]]></source>
<year>1999</year>
<volume>29</volume>
<page-range>106-112</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Scott]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Moss]]></surname>
<given-names><![CDATA[WJ]]></given-names>
</name>
<name>
<surname><![CDATA[Gilani]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Low]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Measles vaccination in HIV-infected children: systematic review and meta-analysis of safety and immunogenicity]]></article-title>
<source><![CDATA[J Infect Dis]]></source>
<year>2011</year>
<volume>204</volume>
<numero>^s1</numero>
<issue>^s1</issue>
<supplement>1</supplement>
<page-range>S164-78</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Scott]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Moss]]></surname>
<given-names><![CDATA[WJ]]></given-names>
</name>
<name>
<surname><![CDATA[Cousens]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The influence of HIV-1 exposure and infection on levels of passively acquired antibodies to measles virus in Zambian infants]]></article-title>
<source><![CDATA[Clin Infect Dis]]></source>
<year>2007</year>
<volume>45</volume>
<page-range>1417-1424</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>17</label><nlm-citation citation-type="book">
<collab>American Academy of Pediatrics</collab>
<article-title xml:lang="en"><![CDATA[Measles]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pickering]]></surname>
<given-names><![CDATA[LK]]></given-names>
</name>
<name>
<surname><![CDATA[Baker]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
<name>
<surname><![CDATA[Kimberlin]]></surname>
<given-names><![CDATA[DW]]></given-names>
</name>
<name>
<surname><![CDATA[Long]]></surname>
<given-names><![CDATA[SS]]></given-names>
</name>
</person-group>
<source><![CDATA[Red Book: 2009 Report of the Committee on Infectious Diseases]]></source>
<year>2009</year>
<edition>28</edition>
<page-range>448</page-range><publisher-loc><![CDATA[Elk Grove Village^eIL IL]]></publisher-loc>
<publisher-name><![CDATA[American Academy of Pediatrics]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B17">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tod]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Carrara]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Levin]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Todd]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Dermatological manifestations of measles infection in hospitalised paediatric patients observed in the 2009-2011 Western Cape epidemic]]></article-title>
<source><![CDATA[S Afr Med J]]></source>
<year>2012</year>
<volume>102</volume>
<page-range>356</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
